Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma
Abstract Background The efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy have been presented and evaluated in previously published TD-NICE study. However, the long-term impacts of patients who received tislelizumab plus chemotherapy followed by surgery were not o...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14686-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|